Recruiting soon

A Randomized, Controlled, Double-Masked Adaptive Design Evaluation of the Safety and Preliminary Efficacy of IVMED-85 on Pediatric Myopia

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

IVMED 85

+ Placebo

Drug
Who is being recruted

Eye Diseases+1

+ Myopia

+ Refractive Errors

From 5 to 16 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-ControlledPhase 1 & 2
Interventional
Study Start: February 2024
See protocol details

Summary

Principal SponsoriVeena Delivery Systems, Inc.
Study ContactSarah Molokhia, RPH, PhD
Last updated: December 13, 2025
Sourced from a government-validated database.Claim as a partner

Study start date: February 1, 2024

Actual date on which the first participant was enrolled.

The goal of this clinical trial is to evaluate the safety and preliminary efficacy of a 1-year course of IVMED-85 eye drops for the treatment of pediatric myopia by assessing its safety effects on visual acuity and its effect on the change and/or progression of myopia. The main question\[s\] it aims to answer are: * Does IVMED 85 improve visual acuity * Does IVMED 85 slow or otherwise change the progression of myopia Participants will use eyedrops twice a day for one year. Researchers will compare IVMED 85 to a placebo.

Official TitleA Randomized, Controlled, Double-Masked Adaptive Design Evaluation of the Safety and Preliminary Efficacy of IVMED-85 on Pediatric Myopia 
NCT05761795
Principal SponsoriVeena Delivery Systems, Inc.
Study ContactSarah Molokhia, RPH, PhD
Last updated: December 13, 2025
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

216 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 5 to 16 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Eye DiseasesMyopiaRefractive ErrorsMyopia, Degenerative

Criteria

Inclusion Criteria: * To be considered for enrollment in the study, the patient must meet all of the following criteria: 1. Age 5 to 16 years and 6 months, three age groups cohorts (5-8), (9-12), and (13-16) (Phase 1 patients will be exclusively age 13-16). 2. Refractive error by cycloplegic refraction in both eyes: myopia -0.75 D to -9.75 D spherical equivalent; astigmatism ≤ 4.00D; anisometropia \<3.00 D 3. Best corrected distance visual acuity better than or equal to Snellen 20/40 (logMAR equivalent 0.3) in both eyes 4. Kmax \>40 D and \<50 D in both eyes 5. Minimum corneal thickness \> 350 microns in both eyes 6. Absence of ocular comorbidities (glaucoma, cataract, anterior segment dysgenesis, corneal scarring, juvenile rheumatoid arthritis, lens subluxation, uveitis, collagen disorders (Ehlers-Danlos, Marfan's syndrome, osteogenesis imperfecta, retinal diseases) in both eyes 7. Written informed consent from a parent or legal guardian and assent from participant 8. Willing and able to comply with clinic visits and study-related procedures. Exclusion Criteria: A patient who meets any of the following criteria, in either eye, will be excluded from the study: 1. Current or previous myopia treatment with atropine, pirenzepine, or other topical anti-muscarinic 2. Significant central corneal scarring or hydrops 3. Known copper allergy 4. Use of rigid gas permeable lenses, including orthokeratology lenses within 90 days of screening 5. Previous cornea, glaucoma, eyelid, strabismus (exotropia or esotropia) or intraocular surgeries 6. Prior history of ocular disorder (e.g., current or prior history of strabismus (exotropia or esotropia), amblyopia, glaucoma, cataract, retinal detachment or nystagmus, or abnormality of the cornea, lens, iris, ciliary body, or central retina) 7. Myopic degeneration with potential visual acuity worse than Snellen 20/40 (logMAR equivalent 0.3) 8. Intraocular pressure \>26 mmHg 9. Medical conditions pre-disposing patient to degenerative myopia or abnormal ocular refractive anatomy (e.g., Stickler Syndrome, Down Syndrome, osteogenesis imperfecta, Ehler's-Danlos Syndrome, Retinopathy of Prematurity) 10. Participation in a clinical trial with use of any investigational drug or treatment within 30 days prior to Visit 1 11. Employees of the study site or their immediate families 12. Pregnancy 13. Hypothyroidism or hyperthyroidism 14. Patient less than 17 Kg weight 15. Planned ophthalmic surgery during the study

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

7 intervention groups are designated in this study

14.286% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
Total subjects n=48 IVMED 85 High Dose BID for 12 month

Group II

Experimental
Total subjects n=6 n=4 IVMED 85 High Dose n=2 placebo BID for 1 month

Group III

Experimental
Total subjects n=48 IVMED 85 Low Dose BID for 12 month

Group IV

Experimental
Total subjects n=6 n=4 IVMED 85 Low Dose n=2 placebo BID for 1 month

Group 5

Experimental
Total subjects n=48 IVMED 85 Mid Dose BID for 12 month

Group 6

Experimental
Total subjects n=6 n=4 IVMED 85 Mid Dose n=2 placebo BID for 1 month

Group 7

Placebo
Total subjects n=54 Placebo BID for 12 month

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has no location dataSave this study to your profile to know when the location data is available. 
Recruiting soonNo study centers